Diflomotecan
Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds[1][2].
Product Specifications
CAS Number
220997-97-7
Product Name Alternative
BN 80915
UNSPSC
12352005
Target
Topoisomerase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/diflomotecan.html
Solubility
10 mM in DMSO
Smiles
O=C(OC1)C[C@](O)(CC)C2=C1C(N3CC4=CC5=CC(F)=C(F)C=C5N=C4C3=C2)=O
Molecular Formula
C21H16F2N2O4
Molecular Weight
398.36
References & Citations
[1]Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009;18 (1) :69-75.|[2]Gelderblom H, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res. 2003;9 (11) :4101-4107.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
039394-ML490 100 µL
OR4F17, NT (OR4F17, OR4F11P, OR4F18, OR4F19, Olfactory receptor 4F17, Olfactory receptor 4F11, Olfactory receptor 4F18, Olfactory receptor 4F19) (MaxLight 490) discontinued
Sign In for Pricing
View Details MBS6175788-01 0.1 mL
SMAD2 (SMAD Family Member 2, JV18, JV18-1, MADH2, MADR2, MGC22139, MGC34440, hMAD-2, hSMAD2) (FITC)
Sign In for Pricing
View Details MBS6175788-02 5x 0.1 mL
SMAD2 (SMAD Family Member 2, JV18, JV18-1, MADH2, MADR2, MGC22139, MGC34440, hMAD-2, hSMAD2) (FITC)
Sign In for Pricing
View Details